Thursday, December 10, 2009

Kineta Gets University Grant

Seattle-based Kineta, a developer of drugs targeted at autoimmune and viral diseases, said this morning that its development partner, Dr. K. George Chandy of the University of California, Irvine, has received a grant related to the firm's lead autoimmune drug. Kineta said that the grant, from the Universeity of California Discovery Fund, covers preclinical studies on its lead autoimmune drug, a Kv1.3 potassium channel blocker. The firm explained the grant will go to support studies to further characterize the drug ahead of in-human clinical trials. Amount of the grant was not announced by the Kineta.